137 related articles for article (PubMed ID: 22136510)
1. Adverse mood symptoms with oral contraceptives.
Poromaa IS; Segebladh B
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):420-7. PubMed ID: 22136510
[TBL] [Abstract][Full Text] [Related]
2. Adverse mood effects of combined oral contraceptives in relation to personality traits.
Borgström A; Odlind V; Ekselius L; Sundström-Poromaa I
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):127-30. PubMed ID: 18760521
[TBL] [Abstract][Full Text] [Related]
3. Patients with adverse mood effects from combined oral contraceptives have lower levels of prepulse inhibition than healthy controls.
Borgström A; Kask K; Gulinello M; Odlind V; Sundström-Poromaa I
Psychoneuroendocrinology; 2008 May; 33(4):487-96. PubMed ID: 18329179
[TBL] [Abstract][Full Text] [Related]
4. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial.
Lundin C; Danielsson KG; Bixo M; Moby L; Bengtsdotter H; Jawad I; Marions L; Brynhildsen J; Malmborg A; Lindh I; Sundström Poromaa I
Psychoneuroendocrinology; 2017 Feb; 76():135-143. PubMed ID: 27923181
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives.
Segebladh B; Borgström A; Odlind V; Bixo M; Sundström-Poromaa I
Contraception; 2009 Jan; 79(1):50-5. PubMed ID: 19041441
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill--a double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive.
Gingnell M; Engman J; Frick A; Moby L; Wikström J; Fredrikson M; Sundström-Poromaa I
Psychoneuroendocrinology; 2013 Jul; 38(7):1133-44. PubMed ID: 23219471
[TBL] [Abstract][Full Text] [Related]
7. Mental Health Symptoms in Oral Contraceptive Users During Short-Term Hormone Withdrawal.
Noachtar IA; Frokjaer VG; Pletzer B
JAMA Netw Open; 2023 Sep; 6(9):e2335957. PubMed ID: 37755829
[TBL] [Abstract][Full Text] [Related]
8. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
9. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
10. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
[TBL] [Abstract][Full Text] [Related]
11. Current perspectives on combination oral contraceptives.
Smith MA; Youngkin EQ
Clin Pharm; 1984; 3(5):485-96. PubMed ID: 6386284
[TBL] [Abstract][Full Text] [Related]
12. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
13. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
14. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
Sehovic N; Smith KP
Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
[TBL] [Abstract][Full Text] [Related]
15. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
16. New regimens with combined oral contraceptive pills--moving away from traditional 21/7 cycles.
Read CM
Eur J Contracept Reprod Health Care; 2010 Dec; 15 Suppl 2():S32-41. PubMed ID: 21091165
[TBL] [Abstract][Full Text] [Related]
17. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives, hormone therapy and cardiovascular risk.
Shapiro S
Climacteric; 2008 Oct; 11(5):355-63. PubMed ID: 18781479
[TBL] [Abstract][Full Text] [Related]
19. Use of an estradiol-based combined oral contraceptives has no influence on attentional bias or depressive symptoms in healthy women.
Scheuringer A; Lundin C; Derntl B; Pletzer B; Sundström Poromaa I
Psychoneuroendocrinology; 2020 Mar; 113():104544. PubMed ID: 31855680
[TBL] [Abstract][Full Text] [Related]
20. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes.
Rapkin AJ; Morgan M; Sogliano C; Biggio G; Concas A
Fertil Steril; 2006 May; 85(5):1371-8. PubMed ID: 16580672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
